An experimental drug from Mineralys Therapeutics significantly lowered blood pressure in patients with treatment-resistant hypertension in a new study, though several stopped taking it because of side effects. https://t.co/5qpbrE619j ...

[Applause] I am Madam Sodium, hypertension's best friend. My vibe is irresistible. I'll hang with HT till the end. Before the refrigerator, you couldn't live without me. I kept food from spoiling and fed every family. Now I'm in the dog house. It is so unfair. But I am here to stay. I am everywhere. Hypertension is sneaky. So, it's about to be lit. If you don't handle your business, your organs and your body will take the hit. So, you might be wondering, why am I starting this conversation on transforming g ...

Company Overview - Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines targeting hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other diseases driven by dysregulated aldosterone [3] - The company's initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor aimed at treating cardiorenal conditions affected by dysregulated aldosterone [3] Financial Results Announcement - Mineralys Therapeutics will report its financial results for the first quarter ended March 31, 2025, after the financial markets close on May 12, 2025 [1] - A live conference call will take place on May 12 at 4:30 p.m. ET, with details provided for both domestic and international participants [2]

Core Insights - Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other diseases related to dysregulated aldosterone [1][3] - The company will host a conference call featuring Dr. Luke Laffin from the Cleveland Clinic to discuss results from the Advance-HTN and Launch-HTN clinical trials, highlighting the unmet medical needs in uncontrolled and resistant hypertension [1] Company Overview - Mineralys Therapeutics is based in Radnor, Pennsylvania, and was founded by Catalys Pacific [3] - The company's lead product candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor aimed at treating cardiorenal conditions influenced by dysregulated aldosterone [3] Upcoming Events - A conference call and webinar will take place on April 1st at 8:00 a.m. ET, where a live webcast will also be available on the company's Investor Relations page [2]